For informational purposes only — not investment advice

← Back to signals

ORKA

Oruka Therapeutics, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)
7.1d↓-16.9%
as of 2026-10-30 · shares short vs 2026-09-30

Fund 13D/13G Filings (2)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

FundForm∆ Shares% of ClassSince FilingFiledSrc
Viking GlobalSC 13G/A−1.2M2.5%
-3.2% vs SPY
-5.5% abs
2026-08-14↗
Viking GlobalSC 13G/A—5.3%
+69.1% vs SPY
+74.6% abs
2026-05-15↗